Skip to content
Private Equity FundPuts its own capital into companiesActive · deal in last 18 monthsLAST VERIFIED Oct 2026 · 12 SOURCES

Vivalto Partners

Also known as Vivalto Partners SAS

Paris healthcare private equity manager (AMF GP-21000024) founded in 2021 by Daniel Caille; first fund generation Vivalto Capital 1 closed at nearly €700M; invests €15M–€50M in European health SMEs.

Private equity manager; distinct from Vivalto Santé, the private hospital group that is one of its portfolio companies.

HEADQUARTERS
Paris, France
FOUNDED
2021
AUM
€700M (2024)
OUTSIDE CAPITAL
Yes
TEAM LISTED
7 people

Focus

STAGES
GrowthBuyout
SECTORS
HealthTechBiotech & Life Sciences
ASSET MIX
Private equityDirect investments
GEOGRAPHY
FranceEurope

Overview

Vivalto Partners is an independent Paris portfolio management company dedicated to healthcare, founded in 2021 by Daniel Caille, founder of the Vivalto Santé hospital group, with Yonel Génin, Sébastien Alauzet, Laurent Dethomas and Charles-Eric François. Its first fund generation, Vivalto Capital 1, closed in January 2024 at nearly €700M from institutional investors, family offices, doctors and healthcare entrepreneurs. It took a controlling stake in Vivalto Santé in late 2021 and invests €15M–€50M in profitable European SMEs and mid-caps valued at €50M–€500M in care services, pharma and consumer health, medical devices and B2B services. Holdings include Laboratoires Delbert, OnO, CBA Informatique Libérale, Linnea and SFAN.

Investment thesis

Profitable, growing healthcare SMEs and mid-caps in France and continental Europe (enterprise value €50M–€500M), often founder-owned companies facing succession, external growth, internationalisation or innovation needs, in four segments: care services, pharma and consumer health (OTC, specialised nutrition, animal health), medical devices and B2B services.

PORTFOLIO (6)

  • Vivalto SantéNOTABLE
    HealthTech · since 2021
  • Laboratoires Delbert
    Biotech & Life Sciences · since 2023
  • OnO
    HealthTech · since 2023
  • CBA Informatique Libérale
    Software & SaaS · since 2023
  • Linnea
    Biotech & Life Sciences · since 2025
  • SFAN
    Biotech & Life Sciences · since 2025

People

  • Daniel Caille
    Président et Partner (co-founder) · source
  • Yonel Génin
    Partner (co-founder) · source
  • Sébastien Alauzet
    Partner (co-founder) · source
  • Laurent Dethomas
    Partner (co-founder) · source
  • Charles-Eric François
    Partner (co-founder) · source
  • Pierre-Henri Flurin
    Directeur médical · source
  • Pauline Bourillon
    Directrice Administrative et Financière · source

Links

Frequently asked questions

Vivalto Partners is a private equity fund based in Paris, France, founded in 2021.

Yes. Vivalto Partners invests its own capital in private companies.

Vivalto Partners invests at Growth and Buyout stages in HealthTech and Biotech & Life Sciences.

Vivalto Partners's stated ticket size is €15M–€50M.

Key people at Vivalto Partners include Daniel Caille (Président et Partner (co-founder)), Yonel Génin (Partner (co-founder)), Sébastien Alauzet (Partner (co-founder)) and Laurent Dethomas (Partner (co-founder)).

Vivalto Partners's investments include Vivalto Santé, Laboratoires Delbert, OnO, CBA Informatique Libérale, Linnea and SFAN.

The most recent publicly reported investment by Vivalto Partners is SFAN (Majority stake (first opening of capital)), announced in Jul 2025.

Yes. Vivalto Partners manages capital from outside investors.